{"id":"NCT01120184","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","officialTitle":"A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07-31","primaryCompletion":"2014-09-30","completion":"2016-09-16","firstPosted":"2010-05-10","resultsPosted":"2017-02-23","lastUpdate":"2024-03-04"},"enrollment":1095,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"docetaxel","otherNames":[]},{"type":"DRUG","name":"paclitaxel","otherNames":[]},{"type":"DRUG","name":"pertuzumab","otherNames":[]},{"type":"DRUG","name":"pertuzumab-placebo","otherNames":[]},{"type":"DRUG","name":"trastuzumab [Herceptin]","otherNames":[]},{"type":"DRUG","name":"trastuzumab emtansine","otherNames":[]}],"arms":[{"label":"Trastuzumab + Taxane (docetaxel or paclitaxel)","type":"EXPERIMENTAL"},{"label":"Trastuzumab emtansine + pertuzumab","type":"EXPERIMENTAL"},{"label":"Trastuzumab emtansine + pertuzumab placebo","type":"EXPERIMENTAL"}],"summary":"This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab (Herceptin) plus taxane (docetaxel or paclitaxel) in participants with HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer. Participants will be randomized to 1 of 3 treatment arms (Arms A, B or C). Arm A will be open-label, whereas Arms B and C will be blinded.","primaryOutcome":{"measure":"Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment","timeFrame":"Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)","effectByArm":[{"arm":"Trastuzumab + Taxane","deltaMin":63.3,"sd":null},{"arm":"Trastuzumab Emtansine + Placebo","deltaMin":64.3,"sd":null},{"arm":"Trastuzumab Emtansine + Pertuzumab","deltaMin":59.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":257,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Canada","Colombia","Czechia","Denmark","France","Germany","Greece","Guatemala","Hungary","Italy","Japan","Malaysia","Mexico","New Zealand","North Macedonia","Panama","Peru","Philippines","Poland","Portugal","Romania","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","The Bahamas","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31146717","23837759","22437872"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":353},"commonTop":["Nausea","Diarrhoea","Fatigue","Headache","Epistaxis"]}}